Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
5 Results Found
AHA Statement on 340B Rebate Guidance
The AHA looks forward to reviewing HRSA’s 340B rebate guidance in more detail and working with the agency on this issue. However, we are concerned that this guidance authorizes a significant departure from how the 340B program has successfully operated for decades and sets a dangerous precedent for possible harmful expansions in the future.
AHA Statement on 340B Report From Senator Cassidy
The AHA appreciates Senator Cassidy’s leadership on 340B issues. As his report correctly observes, the 340B Program was created to help hospitals reach more eligible patients and provide more comprehensive services.
AHA Statement on J&J Abandoning Unlawful Proposed 340B Rebate Plan
The AHA is pleased that Johnson & Johnson has decided to cease implementation of its 340B rebate proposal, which would have harmed patients and 340B providers. We are especially appreciative of HRSA’s efforts to convince J&J to put an end to this unlawful proposal and those members of Congress who demonstrated their firm support of the 340B program.
AHA Statement on Final 340B Administrative Dispute Resolution Process Rule From HHS
The Administration’s final rule for the 340B drug pricing program administrative dispute resolution (ADR) process is an important step in ensuring the integrity of the 340B program. The final rule contains several important process improvements, including a clear timeline for when ADR decisions must be made and an opportunity for reconsideration when parties are dissatisfied with the initial ADR decision.
AHA Statement on Final 340B Remedy
Following years of litigation and a unanimous Supreme Court win, the AHA is very pleased that 340B hospitals finally will be reimbursed in full for what HHS unlawfully withheld from them for five years.